Charlottetown, P.E.I. (November 12, 2021) – BIOVECTRA is proud to be selected as one of Canada’s Top 100 Employers for 2022 and considered amongst some of the country’s leading workplaces.

As one of four Atlantic Canadian companies selected, BIOVECTRA is a fast growing, forward-thinking, global pharmaceutical contract development and manufacturing organization (CDMO) solving complex challenges to meet patient needs.  From modest beginnings as a Startup company designed to give local science talent opportunities, BIOVECTRA has grown into a diverse workplace of more than 550 employees with state-of-the-art manufacturing facilities in Prince Edward Island and Nova Scotia.

People and the growth of talent is hard-coded into BIOVECTRA’s DNA.

Manufacturing Manager Adam MacDonald started with BIOVECTRA as a chemical processing operator right out of high school and now is responsible for 32 employees and ensuring that high-quality product gets delivered to clients. “Mentoring by good people and being supported to take on new roles and responsibilities has led to a full career at BIOVECTRA for me,”says Mr. MacDonald.

“We are thrilled to take our place among Canada’s Top 100 Employers.  This means a great deal to us because BIOVECTRA firmly believes in the idea that valuing our people and creating the conditions for their growth goes hand-in-hand with our success,” explains CEO Oliver Technow.  “People’s contributions are not only welcome, they are essential, because at BIOVECTRA we think of ourselves as relentless problem solvers that also deeply care and respect each other.”

A few of the reasons BIOVECTRA was selected as one of Canada’s Top 100 Employers include a longstanding practice to develop employees through new opportunities and formal education.  It has established a People’s Council to help actively shape workplace culture and has recently expanded health and maternity benefits.

Growth did not stop for BIOVECTRA, even with the challenges brought on by the global pandemic; it onboarded over 200 new employees in 18 months.

“As BIOVECTRA continues to grow, becomes more diverse, and competes in the global market our leadership team is more committed than ever to making employees feel valued, supported, and encouraged to give their best,” reflects Mr. Technow.

Helpful Links

BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients.  Flexibility, creativity, process optimization and compliance are at the heart of our method. With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.

About the 2022 Competition
Now in its 22nd edition, Canada’s Top 100 Employers is an editorial competition that recognizes employers with exceptional human resources programs and forward-thinking workplace policies. Editors at Mediacorp review employers on eight criteria, which have remained consistent since the project’s inception: (1) Physical Workplace; (2) Work Atmosphere & Social; (3) Health, Financial &Family Benefits; (4) Vacation & Time Off; (5) Employee Communications; (6) Performance Management; (7) Training & Skills Development; and (8) Community Involvement. The editors publish detailed ‘reasons for selection’ for these criteria, providing transparency in the selection of winners and a catalogue of best practices for employers and job-seekers alike.

– 30 –

Media Contact
Bobbi Jo Walker
Director, Corporate Communication
(902) 218-7649
[email protected]

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors